These results confirm the role of TNFα in CLL and the importance of addressing this pro-inflammatory cytokine as a therapeutic target in combination regimes with targeted therapies such as rituximab or standard cytotoxic agents like chemotherapy. This evidence concerns the gene TNF and B-cell chronic lymphocytic leukemia.